Autopsy report · NCT00544700

Bevacizumab in Treating Patients Who Have Undergone First-Line Therapy for Metastatic Colorectal Cancer

“Data collection is completed. As no changes in the endpoints were expected in the future, no further data is needed.”

The sponsor’s own words in the registry.

Life of this trial

• Registered 1 month before it started.
• Ran for about 12 years 1 month before it stopped.
• 265 participants enrolled.
• No results are posted on the registry.

Vital statistics

Status

Terminated

Phase

Phase 3

Sponsor

Swiss Cancer Institute

Sponsor type

University, hospital or other

Conditions

Colorectal Cancer

Interventions

bevacizumab; no maintenance

Participants

265

Sites

29

Countries

Switzerland

Trials that died the same way

• Study of Preladenant (MK-3814) Alone and With Pembrolizumab (MK-3475) in Participants With Advanced Solid Tumors (MK-3814A-062)
  “The data did not support study endpoints” (57% match in meaning)
• A Pilot Study of Teacher-Child Interaction Training - Universal in Head Start
  “Intervention and and final data collection point was not completed due to coronavirus school closures in March 2020.” (56% match in meaning)

Look deeper

• The official registry record (the source of truth)
• Record history: every change the sponsor made
• Open it in the database

Everything here comes from the current ClinicalTrials.gov record. The timeline uses the record’s dates; dates marked planned are the sponsor’s plans. The cause of death is an automatic, unverified label. This is research information, not medical advice.